State Street
AUTL

State Street’s Autolus Therapeutics AUTL Stock Holding History

State Street’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Buy
84,409
+869
+1% +$1.36K ﹤0.01% 3921
2026
Q1 		$115K Buy
83,540
+1,712
+2% +$2.6K ﹤0.01% 4000
2025
Q4 		$163K Sell
81,828
-1,290
-2% -$1.98K ﹤0.01% 3945
2025
Q3 		$135K Buy
83,118
+14,801
+22% +$28.9K ﹤0.01% 3994
2025
Q2 		$156K Sell
68,317
-188,198
-73% -$311K ﹤0.01% 3890
2025
Q1 		$398K Sell
256,515
-15
-0% -$30 ﹤0.01% 3642
2024
Q4 		$603K Sell
256,530
-350,014
-58% -$1.18M ﹤0.01% 3583
2024
Q3 		$2.2M Buy
606,544
+10,401
+2% +$41.5K ﹤0.01% 3299
2024
Q2 		$2.07M Buy
596,143
+550,287
+1,200% +$2.37M ﹤0.01% 3307
2024
Q1 		$293K Sell
45,856
-6,531
-12% -$40.7K ﹤0.01% 3783
2023
Q4 		$337K Hold
52,387
– – ﹤0.01% 3744
2023
Q3 		$122K Hold
52,387
– – ﹤0.01% 4063
2023
Q2 		$125K Sell
52,387
-48,860
-48% -$116K ﹤0.01% 4163
2023
Q1 		$182K Buy
101,247
+47,690
+89% +$93.2K ﹤0.01% 4110
2022
Q4 		$102K Buy
53,557
+240
+0.5% +$607 ﹤0.01% 4366
2022
Q3 		$114K Sell
53,317
-610
-1% -$1.81K ﹤0.01% 4413
2022
Q2 		$153K Sell
53,927
-17,973
-25% -$54.7K ﹤0.01% 4329
2022
Q1 		$300K Sell
71,900
-80,472
-53% -$338K ﹤0.01% 4240
2021
Q4 		$791K Buy
152,372
+102,806
+207% +$617K ﹤0.01% 3868
2021
Q3 		$325K Buy
49,566
+27,547
+125% +$174K ﹤0.01% 4151
2021
Q2 		$146K Sell
22,019
-515
-2% -$3.2K ﹤0.01% 4291
2021
Q1 		$129K Hold
22,534
– – ﹤0.01% 3883
2020
Q4 		$201K Sell
22,534
-1,733
-7% -$18.5K ﹤0.01% 3755
2020
Q3 		$282K Buy
24,267
+12,999
+115% +$188K ﹤0.01% 3636
2020
Q2 		$181K Sell
11,268
-576
-5% -$6.39K ﹤0.01% 3625
2020
Q1 		$71K Sell
11,844
-864
-7% -$7.99K ﹤0.01% 3642
2019
Q4 		$168K Sell
12,708
-192
-1% -$2.51K ﹤0.01% 3650
2019
Q3 		$160K Buy
+12,900
New +$170K ﹤0.01% 3630

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street's AUTL Position: Q2 2026 in Review

State Street increased its Autolus Therapeutics (AUTL) stake by 1% in Q2 2026, buying an estimated $1.36K and bringing the position to 84,409 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #3921.

State Street first reported a position in AUTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.2M in Q3 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • State Street held 84,409 shares of Autolus Therapeutics worth $135K as of Q2 2026.
  • State Street bought 869 Autolus Therapeutics shares in Q2 2026, an estimated $1.36K.
  • Autolus Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3921 holding.
  • State Street first reported a position in Autolus Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • State Street's Autolus Therapeutics position peaked at $2.2M in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.